Medicago to present at the 2008 BIO International Convention in San Diego, CA

    QUEBEC CITY, June 16 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"),
today announced that it will be presenting at the 2008 BIO International
Convention from June 17-20, 2008, at the San Diego Convention Center, San
Diego, California. Ms. Brigitte Barbeau, VP Manufacturing, will present
Medicago's unique solution for the rapid and cost effective production of
pandemic flu vaccines in a Breakout Session organized by Sanofi Pasteur
entitled, "Beyond the Bench: Protein Production Systems at an Industrial
Scale", being held on Thursday, June 19 at 10:30am PDT in Room 29B. This
session will discuss recent advances in manufacturing processes for
protein-based vaccines and therapeutics and consider the advantages they can
bring to large-scale protein production.

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at

    Forward- Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    The TSX Venture Exchange assumes no responsibility for the content or
    accuracy of this press release

    %SEDAR: 00023641EF

For further information:

For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Investor relations: The Equicom Group Inc., Arianna
Vanin, (514) 844-4680,

Organization Profile

Medicago Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890